The prevalence of cancer in patients with multiple sclerosis (MS) who received rituximab: a systematic review and meta-analysis

Neurologia Pub Date : 2025-01-01 DOI:10.1016/j.nrleng.2022.07.004

O. Mirmosayyeb , V. Shaygannejad , N. Ebrahimi , H. Ghoshouni , M. Ghajarzadeh

{"title":"The prevalence of cancer in patients with multiple sclerosis (MS) who received rituximab: a systematic review and meta-analysis","authors":"O. Mirmosayyeb , V. Shaygannejad , N. Ebrahimi , H. Ghoshouni , M. Ghajarzadeh","doi":"10.1016/j.nrleng.2022.07.004","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><div>To estimate the pooled prevalence of cancer in patients with multiple sclerosis (MS) cases who were under treatment with rituximab.</div></div><div><h3>Methods</h3><div>We searched PubMed, Scopus, EMBASE, Web of Science, and google scholar along with gray literature up to April 2021.</div><div>The search strategy included the MeSH and text words as ((“CD20 Antibody” AND Rituximab) OR “Rituximab CD20 Antibody” OR Mabthera OR “IDEC-C2B8 Antibody” OR “IDEC C2B8 Antibody” OR IDEC-C2B8 OR “IDEC C2B8” OR GP2013 OR Rituxan OR rituximab) AND ((Sclerosis AND multiple) OR (sclerosis AND disseminated) OR \"disseminated sclerosis\" OR \"multiple sclerosis\" OR \"acute fulminating\").</div></div><div><h3>Results</h3><div>The literature search revealed 3577 articles, after deleting duplicates 2066 remained. For the meta-analysis, 22 studies were included. Totally, 15599 patients were enrolled while 133 cancers were detected.</div><div>The pooled prevalence of cancer in MS patients under treatment with rituximab is 1in 100,000 (I2 = 99.9%, p < 0.001).</div></div><div><h3>Conclusion</h3><div>The results of this systematic review and meta-analysis show that the pooled prevalence of cancer in MS patients who received rituximab is 1 in 100,000 cases.</div></div>","PeriodicalId":94155,"journal":{"name":"Neurologia","volume":"40 1","pages":"Pages 41-47"},"PeriodicalIF":0.0000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neurologia","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2173580822000906","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Objective

To estimate the pooled prevalence of cancer in patients with multiple sclerosis (MS) cases who were under treatment with rituximab.

Methods

We searched PubMed, Scopus, EMBASE, Web of Science, and google scholar along with gray literature up to April 2021.

The search strategy included the MeSH and text words as ((“CD20 Antibody” AND Rituximab) OR “Rituximab CD20 Antibody” OR Mabthera OR “IDEC-C2B8 Antibody” OR “IDEC C2B8 Antibody” OR IDEC-C2B8 OR “IDEC C2B8” OR GP2013 OR Rituxan OR rituximab) AND ((Sclerosis AND multiple) OR (sclerosis AND disseminated) OR "disseminated sclerosis" OR "multiple sclerosis" OR "acute fulminating").

Results

The literature search revealed 3577 articles, after deleting duplicates 2066 remained. For the meta-analysis, 22 studies were included. Totally, 15599 patients were enrolled while 133 cancers were detected.

The pooled prevalence of cancer in MS patients under treatment with rituximab is 1in 100,000 (I2 = 99.9%, p < 0.001).

Conclusion

The results of this systematic review and meta-analysis show that the pooled prevalence of cancer in MS patients who received rituximab is 1 in 100,000 cases.

查看原文本刊更多论文

接受利妥昔单抗治疗的多发性硬化症（MS）患者的癌症发病率：系统综述和荟萃分析。

目的估算接受利妥昔单抗治疗的多发性硬化症（MS）患者的癌症发病率：我们检索了 PubMed、Scopus、EMBASE、Web of Science 和 google scholar 以及截至 2021 年 4 月的灰色文献。检索策略包括 MeSH 和文本词（（"CD20 抗体 "和利妥昔单抗）或 "利妥昔单抗 CD20 抗体 "或 Mabthera 或 "IDEC-C2B8 抗体 "或 "IDEC C2B8 抗体 "或 IDEC-C2B8 "或 "IDEC C2B8 "或 GP2013 或利妥昔单抗或利妥昔单抗）和（（硬化症和多发性）或（硬化症和播散性）或 "播散性硬化症 "或 "多发性硬化症 "或 "急性发热"）。结果：文献检索共发现 3577 篇文章，删除重复文章后剩余 2066 篇。荟萃分析共纳入 22 项研究。共纳入 15599 名患者，发现 133 例癌症。在接受利妥昔单抗治疗的多发性硬化症患者中，癌症的总发病率为十万分之一（I2 = 99.9%，P 结论：癌症的总发病率为十万分之一：这项系统回顾和荟萃分析的结果显示，接受利妥昔单抗治疗的多发性硬化症患者的癌症发病率为十万分之一。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Neurologia

自引率

0.00%

发文量

审稿时长

53 weeks